Skip to main content
Premium Trial:

Request an Annual Quote

Singlera Genomics, Yale Partner on NIPT Clinical Trial

NEW YORK (GenomeWeb) – Noninvasive prenatal testing startup Singlera Genomics has partnered on a clinical trial with researchers at Yale University to evaluate Singlera's technology for noninvasive prenatal testing of chromosomal aneuploidy and fetal DNA fraction measurement.

Yuan Gao from Johns Hopkins University and Kun Zhang from the University of California, San Diego cofounded La Jolla, California-based Singlera in June 2014. The company has exclusively licensed several technologies developed in Zhang's UCSD laboratory for its proprietary NIPT, which has a turnaround time of one to two days, the company said.

Researchers from Yale, led by Michael Paidas, professor and vice chair of obstetrics, will evaluate Singlera's test in a clinical trial. According to the company, an advantage of the test compared to other NIPTs is that it simultaneously measures fetal DNA fraction, which has been observed to be lower in women with a higher body mass index.

"Having a reliable screen for patients with increased body mass index would be transformative and significantly decrease invasive testing in this population," Paidas said in a statement. 

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.